Doubly Constrained C-terminal of Roc (COR) Domain-Derived Peptides Inhibit Leucine-Rich Repeat Kinase 2 (LRRK2) Dimerization

Missense mutations along the leucine-rich repeat kinase 2 (LRRK2) protein are a major contributor to Parkinson’s Disease (PD), the second most commonly occurring neurodegenerative disorder worldwide. We recently reported the development of allosteric constrained peptide inhibitors that target and downregulate LRRK2 activity through disruption of LRRK2 dimerization. In this study, we designed doubly constrained peptides with the objective of inhibiting C-terminal of Roc (COR)–COR mediated dimerization at the LRRK2 dimer interface. We show that the doubly constrained peptides are cell-permeant, bind wild-type and pathogenic LRRK2, inhibit LRRK2 dimerization and kinase activity, and inhibit LRRK2-mediated neuronal apoptosis, and in contrast to ATP-competitive LRRK2 kinase inhibitors, they do not induce the mislocalization of LRRK2 to skein-like structures in cells. This work highlights the significance of COR-mediated dimerization in LRRK2 activity while also highlighting the use of doubly constrained peptides to stabilize discrete secondary structural folds within a peptide sequence.

[1]  Nicholas E. Propson,et al.  Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson’s disease , 2022, Science Translational Medicine.

[2]  E. Kennedy,et al.  Targeting the WASF3 Complex to Suppress Metastasis. , 2022, Pharmacological research.

[3]  E. Kennedy,et al.  Allosteric Inhibition of Parkinson's-Linked LRRK2 by Constrained Peptides. , 2021, ACS chemical biology.

[4]  A. Myasnikov,et al.  Structural analysis of the full-length human LRRK2 , 2021, Cell.

[5]  D. Berwick,et al.  The development of inhibitors of leucine‐rich repeat kinase 2 (LRRK2) as a therapeutic strategy for Parkinson's disease: the current state of play , 2021, British journal of pharmacology.

[6]  Samara L. Reck-Peterson,et al.  Structure of LRRK2 in Parkinson’s disease and model for microtubule interaction , 2020, Nature.

[7]  S. Boularand,et al.  Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity , 2020, Proceedings of the National Academy of Sciences.

[8]  Matthew L. Maddess,et al.  LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits , 2020, Science Translational Medicine.

[9]  Derek N Woolfson,et al.  BAlaS: fast, interactive and accessible computational alanine-scanning using BudeAlaScan , 2020, Bioinform..

[10]  S. Boularand,et al.  Dopaminergic Neurodegeneration Induced by Parkinson’s Disease-Linked G2019S LRRK2 is Dependent on Kinase and GTPase Activity , 2019, bioRxiv.

[11]  D. Berwick,et al.  LRRK2 Biology from structure to dysfunction: research progresses, but the themes remain the same , 2019, Molecular Neurodegeneration.

[12]  S. Pfeffer,et al.  PPM1H phosphatase counteracts LRRK2 signaling by selectively dephosphorylating Rab proteins , 2019, bioRxiv.

[13]  R. Sessions,et al.  Predicting and Experimentally Validating Hot-Spot Residues at Protein–Protein Interfaces , 2019, ACS chemical biology.

[14]  Katerina Melachroinou,et al.  Kinase activity of mutant LRRK2 manifests differently in hetero-dimeric vs. homo-dimeric complexes. , 2019, The Biochemical journal.

[15]  Dimitrios Vlachakis,et al.  A motif within the armadillo repeat of Parkinson’s-linked LRRK2 interacts with FADD to hijack the extrinsic death pathway , 2018, Scientific Reports.

[16]  E. Kennedy,et al.  Targeting kinase signaling pathways with constrained peptide scaffolds. , 2017, Pharmacology & therapeutics.

[17]  Hardy J Rideout,et al.  Neuronal death signaling pathways triggered by mutant LRRK2. , 2017, Biochemical Society transactions.

[18]  G. Hadjigeorgiou,et al.  Activation of FADD-Dependent Neuronal Death Pathways as a Predictor of Pathogenicity for LRRK2 Mutations , 2016, PloS one.

[19]  Mark R Cookson,et al.  LRRK2 Pathways Leading to Neurodegeneration , 2015, Current Neurology and Neuroscience Reports.

[20]  Aaron M. Beedle,et al.  Inhibiting EGFR Dimerization Using Triazolyl-Bridged Dimerization Arm Mimics , 2015, PloS one.

[21]  Paula Katavolos,et al.  Effect of selective LRRK2 kinase inhibition on nonhuman primate lung , 2015, Science Translational Medicine.

[22]  J. Wells,et al.  Small-molecule inhibitors of protein-protein interactions: progressing toward the reality. , 2014, Chemistry & biology.

[23]  L. Walensky,et al.  Hydrocarbon-Stapled Peptides: Principles, Practice, and Progress , 2014, Journal of medicinal chemistry.

[24]  Mark Ellisman,et al.  LRRK2 Parkinson disease mutations enhance its microtubule association. , 2011, Human molecular genetics.

[25]  Z. Berger,et al.  Membrane localization of LRRK2 is associated with increased formation of the highly active LRRK2 dimer and changes in its phosphorylation. , 2010, Biochemistry.

[26]  A. West,et al.  Dependence of Leucine-rich Repeat Kinase 2 (LRRK2) Kinase Activity on Dimerization* , 2009, The Journal of Biological Chemistry.

[27]  M. Cookson,et al.  The Parkinson Disease-associated Leucine-rich Repeat Kinase 2 (LRRK2) Is a Dimer That Undergoes Intramolecular Autophosphorylation* , 2008, Journal of Biological Chemistry.

[28]  Christopher L. McClendon,et al.  Reaching for high-hanging fruit in drug discovery at protein–protein interfaces , 2007, Nature.

[29]  L. Bubacco,et al.  Molecular Insights and Functional Implication of LRRK2 Dimerization. , 2017, Advances in neurobiology.

[30]  A. Wittinghofer,et al.  Revisiting the Roco G-protein cycle. , 2015, The Biochemical journal.

[31]  Bertram Müller-Myhsok,et al.  The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval. , 2004, American journal of human genetics.